3B Blackbio DX Ltd

Q3 FY25Healthcare Services

3B Blackbio DX Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,406

Market cap₹1.1K Cr

P/E20.4

Updated24 Sept 2026

Read4 min read

Based on 3B Blackbio DX Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. EBITDA Q3 FY 2024-25: Rs.

From 3B Blackbio DX Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. 44%)
Profit Before Tax Q3 FY 2024-25: ₹1,779.62 Lakh vs ₹1,115.19 Lakh (↑ approx. 60%)
Profit After Tax Q3 FY 2024-25: ₹1,349.53 Lakh vs ₹851.68 Lakh (↑ approx. 58%)
Diagnostics Division Revenue Q3 FY 2024-25: ₹2,328.30 Lakh (including TRUPCR Europe sales) vs ₹1,531.37 Lakh (↑ approx. 52%)
Export Sales Q3 FY 2024-25: ₹587.24 Lakh vs ₹267.20 Lakh (↑ approx. 120%)
TRUPCR Europe Q3 FY 2024-25 sales: GBP 417,623 vs GBP 133,508 (↑ approx. 213%)
Business Outlook:
Molecular Diagnostics to grow 20-25% annually
Export/international business targeted growth of 20-25%

2 more points management made on revenue & sales performance

Profitability & Margins

- **EBITDA Q3 FY 2024-25:** Rs. 1,783.89 Lakh **EBITDA Q3 FY 2023-24:** Rs. 1,170.47 Lakh **YoY Increase:** Rs. 613.42 Lakh (~52.4%) - **Profit After Tax (PAT) Q3 FY 2024-25:** Rs. 1,349.53 Lakh **PAT Q3 FY 2023-24:** Rs. 851.68 Lakh **YoY Increase:** Rs. 497.85 Lakh (~58.5%) - **Revenue from Operations Q3 FY 2024-25:** Rs. 2,539.25 Lakh **Revenue from Operations Q3 FY 2023-24:** Rs. 1,766.89 Lakh **Implied Operating Margin:** EBITDA/Revenue for Q3 FY 2024-25 = ~70.3%, Q3 FY 2023-24 = ~66.3% - **Explicit Margin Outlook:** The presentation does not state any specific operating margin or EBITDA margin outlook; however, it projects an overall sales growth of 20-25% for the fiscal year.

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The company is continuously investing in additional manufacturing and R&D facilities/capacities to cater to existing business verticals.
Focus on designing and launching new products to meet increasing market needs, especially in syndromic testing panels, maintaining first-mover advantage (Page 35).
Deployment of some funds planned in a joint venture in Manchester, UK, depending on need (Page 35).
Introduction of a new automated extraction system under OEM for DNA/RNA extraction now available for sales/reagent rental, supporting customer processes (Page 33).

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The presentation does not explicitly mention any fundraising through debt or equity in the disclosed pages.
There is no direct reference to changes in borrowings or net debt levels.
The Agrochemical division section (Page 6) states the business operates with minimal debt, consistent with prior projections.
Financial highlights show increased revenue, profits, reserves, and earnings per share but do not indicate new debt or equity raising.

2 more points management made on fundraising & capital structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation reports the following regarding order book, order inflow, or pending orders: - An export order of ₹137 lakh (US$165,000) was received and exported in Q3 FY 2024-25 (Page 18). - This export order may be a yearly order and might not repeat in subsequent quarters (Page 18). - Excluding this order, export sales were ₹450 lakh in Q3 FY 2024-25 (Page 18).

2 more points management made on order book & pipeline

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What 3B Blackbio DX Ltd's management said in earlier quarters

Others in Healthcare Services this season

Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
Rainbow Child. (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Dr Lal Pathlabs Ltd (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Thyrocare Technologies Ltd (Q3 FY25)
Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY. Key concall takeaways from Thyrocare Technologies…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q3 FY25 results?

Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. EBITDA Q3 FY 2024-25: Rs.

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in additional manufacturing and R&D facilities/capacities to cater to existing business verticals.

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.